Table 3 Cognitive categoriesa at the end of year 1 and year 2
|  | Overall population | Subpopulation (aged < 6 years at baseline) | ||
|---|---|---|---|---|
|  | Idursulfase-IT in RCT (n = 34) | No idursulfase-IT in RCT (n = 15) | Idursulfase-IT in RCT (n = 28) | No idursulfase-IT in RCT (n = 12) |
Cognitive category | Year 1 (n = 29) | Year 1 (n = 15) | Year 1 (n = 25) | Year 1 (n = 12) |
Above-average cognitive growth rate | 2/29 (6.9%) | 0 | 2/25 (8.0%) | 0 |
Average cognitive growth rate | 19/29 (65.5%) | 8/15 (53.3%) | 17/25 (68.0%) | 6/12 (50.0%) |
Below-average cognitive growth rate | 0 | 0 | 0 | 0 |
Plateauing cognitive functioning | 6/29 (20.7%) | 4/15 (26.7%) | 5/25 (20.0%) | 4/12 (33.3%) |
Deteriorating cognitive functioning | 2/29 (6.9%) | 3/15 (20.0%) | 1/25 (4.0%) | 2/12 (16.7%) |
Cognitive category | Year 2 (n = 27) | Year 2 (n = 12) | Year 2 (n = 25) | Year 2 (n = 11) |
|---|---|---|---|---|
Above-average cognitive growth rate | 1/27 (3.7%) | 0 | 1/25 (4.0%) | 0 |
Average cognitive growth rate | 12/27 (44.4%) | 5/12 (41.7%) | 11/25 (44.0%) | 4/11 (36.4%) |
Below-average cognitive growth rate | 1/27 (3.7%) | 1/12 (8.25%) | 1/25 (4.0%) | 1/11 (9.1%) |
Plateauing cognitive functioning | 10/27 (37.0%) | 5/12 (41.7%) | 9/25 (36.0%) | 5/11 (45.5%) |
Deteriorating cognitive functioning | 3/27 (11.1%) | 1/12 (8.25%) | 3/25 (12.0%) | 1/11 (9.1%) |